Literature DB >> 14592826

Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].

Saeid Abroun1, Hideaki Ishikawa, Naohiro Tsuyama, Shangqin Liu, Fu-Jun Li, Ken-ichiro Otsuyama, Xu Zheng, Masanori Obata, Michio M Kawano.   

Abstract

Interleukin-6 (IL-6) is a growth and antiapoptotic factor for human myeloma cells. The autocrine loop and increased expression of the growth factor receptors have been postulated as the mechanisms of tumorigenesis. Here we show that IL-6 stimulation induced the phosphorylation of insulin-like growth factor-I (IGF-I) receptors in a human myeloma cell line, NOP2, highly expressing IL-6 receptor alpha (IL-6R alpha) and in the IL-6R alpha-transfected U266 cell line. IL-6-dependent complex formation of IL-6R alpha with IGF-I receptor beta was found in NOP2 where IL-6R alpha colocalized with IGF-I receptors at lipid rafts. Moreover, the IL-6-induced phosphorylation of IGF-I receptor beta was not blocked by a Janus kinase 2 (Jak2) inhibitor. In addition to the activation of the signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2, IL-6 stimulation led to the activation of Akt, presumably following the phosphorylation of IGF-I receptors. Thus, our results suggest that in NOP2, IL-6R alpha and IGF-I receptors exist on the plasma membrane in close proximity, facilitating the efficient assembly of 2 receptors in response to IL-6. The synergistic effects of highly expressed IL-6R alpha on IGF-I receptor-mediated signals provide a novel insight into the Jak-independent IL-6 signaling mechanism of receptor cross-talk in human myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592826     DOI: 10.1182/blood-2003-07-2187

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies.

Authors:  Lauren R Teras; Cari M Kitahara; Brenda M Birmann; Patricia A Hartge; Sophia S Wang; Kim Robien; Alpa V Patel; Hans-Olov Adami; Elisabete Weiderpass; Graham G Giles; Pramil N Singh; Michael Alavanja; Laura E Beane Freeman; Leslie Bernstein; Julie E Buring; Graham A Colditz; Gary E Fraser; Susan M Gapstur; J Michael Gaziano; Edward Giovannucci; Jonathan N Hofmann; Martha S Linet; Gila Neta; Yikyung Park; Ulrike Peters; Philip S Rosenberg; Catherine Schairer; Howard D Sesso; Meir J Stampfer; Kala Visvanathan; Emily White; Alicja Wolk; Anne Zeleniuch-Jacquotte; Amy Berrington de González; Mark P Purdue
Journal:  Br J Haematol       Date:  2014-05-23       Impact factor: 6.998

Review 2.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

4.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

Review 5.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

6.  The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling.

Authors:  Antoine David; Simone Zocchi; Alexis Talbot; Caroline Choisy; Ashley Ohnona; Julien Lion; Wendy Cuccuini; Jean Soulier; Bertrand Arnulf; Jean-Christophe Bories; Michele Goodhardt; David Garrick
Journal:  Leukemia       Date:  2020-09-03       Impact factor: 11.528

7.  Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.

Authors:  Jing Yang; Xiang Zhang; Ji Wang; Jianfei Qian; Liang Zhang; Michael Wang; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

8.  Body mass index, physical activity, and risk of multiple myeloma.

Authors:  Brenda M Birmann; Edward Giovannucci; Bernard Rosner; Kenneth C Anderson; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-07       Impact factor: 4.254

9.  Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.

Authors:  Vidya Ramakrishnan; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2018-04-09       Impact factor: 4.030

10.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.